Paper25399643
Targeting protein kinases with selective and semipromiscuous covalent inhibitors.
Miller RM and 1 other. Methods Enzymol, 2014. Cited by 31 papers, by iCite.
Cite this record
ConductScience Library. Targeting protein kinases with selective and semipromiscuous covalent inhibitors. Papers, record 25399643. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25399643
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Drug Design | Major topic |
| Models, Chemical | Major topic |
| Protein Kinase Inhibitors | Major topic |
| Protein Kinases | Major topic |
| Animals | |
| Biocatalysis | |
| Catalysis | |
| Catalytic Domain | |
| Humans | |
| Lysine | |
| Protein Conformation |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R01 GM071434 | NIGMS NIH HHS | United States | R01GM071434 | PubMed and NIH |
Source NIH RePORTER
References49
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16868029 | RSK and MSK in MAP kinase signalling. | J Cell Sci | 2006 | https://conductscience.org/library/papers/16868029 | PubMed |
| 2 | 16763566 | The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. | EMBO J | 2006 | https://conductscience.org/library/papers/16763566 | PubMed |
| 3 | 17154430 | Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. | ChemMedChem | 2007 | https://conductscience.org/library/papers/17154430 | PubMed |
| 4 | 17259979 | A clickable inhibitor reveals context-dependent autoactivation of p90 RSK. | Nat Chem Biol | 2007 | https://conductscience.org/library/papers/17259979 | PubMed |
| 5 | 17142297 | Evidence for direct regulation of myocardial Na+/H+ exchanger isoform 1 phosphorylation and activity by 90-kDa ribosomal S6 kinase (RSK): effects of the novel and specific RSK inhibitor fmk on responses to alpha1-adrenergic stimulation. | Mol Pharmacol | 2007 | https://conductscience.org/library/papers/17142297 | PubMed |
| 6 | 17721511 | Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. | Nat Biotechnol | 2007 | https://conductscience.org/library/papers/17721511 | PubMed |
| 7 | 17850214 | The selectivity of protein kinase inhibitors: a further update. | Biochem J | 2007 | https://conductscience.org/library/papers/17850214 | PubMed |
| 8 | 19716794 | RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile/invasive gene program and phenotype in epithelial cells. | Mol Cell | 2009 | https://conductscience.org/library/papers/19716794 | PubMed |
| 9 | 20338520 | A structure-guided approach to creating covalent FGFR inhibitors. | Chem Biol | 2010 | https://conductscience.org/library/papers/20338520 | PubMed |
| 10 | 20234090 | p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells. | J Clin Invest | 2010 | https://conductscience.org/library/papers/20234090 | PubMed |
| 11 | 21062900 | A genome-wide RNAi screen identifies multiple RSK-dependent regulators of cell migration. | Genes Dev | 2010 | https://conductscience.org/library/papers/21062900 | PubMed |
| 12 | 21322567 | Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors. | J Med Chem | 2011 | https://conductscience.org/library/papers/21322567 | PubMed |
| 13 | 21455239 | The resurgence of covalent drugs. | Nat Rev Drug Discov | 2011 | https://conductscience.org/library/papers/21455239 | PubMed |
| 14 | 21627121 | Irreversible Nek2 kinase inhibitors with cellular activity. | J Med Chem | 2011 | https://conductscience.org/library/papers/21627121 | PubMed |
| 15 | 21700206 | In situ kinase profiling reveals functionally relevant properties of native kinases. | Chem Biol | 2011 | https://conductscience.org/library/papers/21700206 | PubMed |
| 16 | 21765410 | High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases. | Nat Methods | 2011 | https://conductscience.org/library/papers/21765410 | PubMed |
| 17 | 22187936 | Regulation and function of the RSK family of protein kinases. | Biochem J | 2012 | https://conductscience.org/library/papers/22187936 | PubMed |
| 18 | 22284350 | How chemoproteomics can enable drug discovery and development. | Chem Biol | 2012 | https://conductscience.org/library/papers/22284350 | PubMed |
| 19 | 22466421 | Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles. | Nat Chem Biol | 2012 | https://conductscience.org/library/papers/22466421 | PubMed |
| 20 | 22621397 | Irreversible protein kinase inhibitors: balancing the benefits and risks. | J Med Chem | 2012 | https://conductscience.org/library/papers/22621397 | PubMed |
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 31 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40964339 | High throughput screening of eukaryotic release factor 1 variants to enhance noncanonical amino acid incorporation. | bioRxiv | 2025 | https://conductscience.org/library/papers/40964339 | PubMed |
| 39366946 | Reversible covalent c-Jun N-terminal kinase inhibitors targeting a specific cysteine by precision-guided Michael-acceptor warheads. | Nat Commun | 2024 | https://conductscience.org/library/papers/39366946 | PubMed |
| 39366929 | Targeting a key protein-protein interaction surface on mitogen-activated protein kinases by a precision-guided warhead scaffold. | Nat Commun | 2024 | https://conductscience.org/library/papers/39366929 | PubMed |
| 36793448 | Bioconjugate Platform for Iterative Backbone N-Methylation of Peptides. | ACS Catal | 2022 | https://conductscience.org/library/papers/36793448 | PubMed |
| 35364007 | Inhibiting a dynamic viral protease by targeting a non-catalytic cysteine. | Cell Chem Biol | 2022 | https://conductscience.org/library/papers/35364007 | PubMed |
| 32042200 | Development of a covalent inhibitor of gut bacterial bile salt hydrolases. | Nat Chem Biol | 2020 | https://conductscience.org/library/papers/32042200 | PubMed |
| 30974337 | Future prospects for noncanonical amino acids in biological therapeutics. | Curr Opin Biotechnol | 2019 | https://conductscience.org/library/papers/30974337 | PubMed |
| 30837567 | Regional perturbation of gene transcription is associated with intrachromosomal rearrangements and gene fusion transcripts in high grade ovarian cancer. | Sci Rep | 2019 | https://conductscience.org/library/papers/30837567 | PubMed |
| 30533581 | The Allosteric Site on SHP2's Protein Tyrosine Phosphatase Domain is Targetable with Druglike Small Molecules. | ACS Omega | 2018 | https://conductscience.org/library/papers/30533581 | PubMed |
| 29626545 | Hypoxia-selective allosteric destabilization of activin receptor-like kinases: A potential therapeutic avenue for prophylaxis of heterotopic ossification. | Bone | 2018 | https://conductscience.org/library/papers/29626545 | PubMed |
| 28920684 | Stilbene Boronic Acids Form a Covalent Bond with Human Transthyretin and Inhibit Its Aggregation. | J Med Chem | 2017 | https://conductscience.org/library/papers/28920684 | PubMed |
| 28701380 | Prediction of intracellular exposure bridges the gap between target- and cell-based drug discovery. | Proc Natl Acad Sci U S A | 2017 | https://conductscience.org/library/papers/28701380 | PubMed |
| 28640596 | Drug-Target Kinetics in Drug Discovery. | ACS Chem Neurosci | 2018 | https://conductscience.org/library/papers/28640596 | PubMed |
| 27598117 | The Search for Covalently Ligandable Proteins in Biological Systems. | Molecules | 2016 | https://conductscience.org/library/papers/27598117 | PubMed |
| 27059428 | Modular Synthesis of Novel Macrocycles Bearing α,β-Unsaturated Chemotypes through a Series of One-Pot, Sequential Protocols. | Chemistry | 2016 | https://conductscience.org/library/papers/27059428 | PubMed |
| 26159564 | Automated computational screening of the thiol reactivity of substituted alkenes. | J Comput Aided Mol Des | 2015 | https://conductscience.org/library/papers/26159564 | PubMed |
Genes17
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25399643
GET https://conductscience.org/api/papers/v1/25399643/references?page=2